Markets:

Overview

News

Currencies

International

Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

21.63 -0.19 (-0.87%)

Streaming Delayed Price Updated: 9:44 AM EDT, Apr 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

3 Russell 2000 Stocks with Questionable Fundamentals

June 11, 2025

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...

Via StockStory

3 Small-Cap Stocks Walking a Fine Line

May 29, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know

May 27, 2025

A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports,...

Via StockStory

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Earnings Outlook For Amphastar Pharma ↗

May 06, 2025

Via Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024

February 27, 2025

Via ACCESS Newswire

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers

May 22, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 22, 2025

Via ACCESS Newswire

AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – A Potentially Undervalued Stock Worth Watching ↗

May 17, 2025

AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) offers strong profitability and an undervalued stock price, making it a candidate for value investors. Check the full analysis for details.

Via Chartmill

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗

May 12, 2025

Via Benzinga

Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference

May 09, 2025

Via ACCESS Newswire

Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 Sales Targets

May 07, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74...

Via StockStory

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

May 07, 2025

Via ACCESS Newswire

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential ↗

May 01, 2025

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential

Via Chartmill

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025

April 30, 2025

Via ACCESS Newswire

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

April 29, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest

April 28, 2025

Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is an undervalued gem with solid fundamentals. ↗

April 25, 2025

Uncover the potential of AMPHASTAR PHARMACEUTICALS IN, an undervalued stock. NASDAQ:AMPH maintains a strong financial position and offers an appealing valuation.

Via Chartmill

2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About

April 24, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

2 Reasons to Like AMPH and 1 to Stay Skeptical

April 15, 2025

What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. This was partly due to its softer quarterly results...

Via StockStory

Topics Supply Chain

Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

April 03, 2025

Via ACCESS Newswire

International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award

March 28, 2025

Via ACCESS Newswire

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), an undervalued stock with good fundamentals. ↗

March 27, 2025

Take a closer look at AMPHASTAR PHARMACEUTICALS IN , a remarkable value stock. NASDAQ:AMPH excels in fundamentals and maintains a very reasonable valuation.

Via Chartmill

Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks

March 13, 2025

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at generic pharmaceuticals stocks, starting...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference

March 05, 2025

Via ACCESS Newswire

Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers

March 05, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Specialty Pharma Amphastar Stock Falls On Lower Than Expected Q4 Earnings, Analyst Sees Competitive Headwinds ↗

February 28, 2025

Amphastar's Q4 sales grew 20% to $186.5M, missing estimates. Primatene MIST surpassed $100M in annual sales, while Baqsimi saw strong growth.

Via Benzinga

Amphastar: Earnings Miss, Margins Drop ↗

February 28, 2025

Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.

Via The Motley Fool

Topics Earnings

Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%

February 27, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) missed Wall Street’s revenue expectations in Q4 CY2024 as sales rose 4.7% year on year to $186.5 million. Its non-GAAP profit of $0.92 per...

Via StockStory

Topics Artificial Intelligence Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.